Investment Rating - The report maintains a "Buy" rating for the company [4][6]. Core Insights - The commercialization of Sipuqibai monoclonal antibody is rapidly expanding, with sales revenue of approximately 170 million RMB in the first half of 2025, and the company forecasts peak sales to exceed 5 billion RMB [2][4]. - The company focuses on the field of type 2 inflammation-related diseases and is building a specialized sales team in the autoimmune sector, enhancing drug accessibility across over 30 provinces and 240+ cities, covering more than 1,400 hospitals [2][4]. - The company is committed to deepening its potential pipeline, with a broad layout for future products and a large patient population to target [3][4]. Financial Performance and Forecast - For the first half of 2025, the company achieved a revenue of 499 million RMB, a year-on-year increase of 812%, with drug sales contributing about 170 million RMB and collaboration income around 330 million RMB [1][4]. - The adjusted net profit forecast for 2025 is -624 million RMB, improved from the previous estimate of -737 million RMB, while the 2026 forecast is adjusted to -434 million RMB from -304 million RMB [4][5]. - The revenue projections for 2025, 2026, and 2027 are 680 million RMB, 1.23 billion RMB, and 2.03 billion RMB respectively, with significant growth rates anticipated [5][10].

基于康诺亚今年上半年业绩及管线研发进展，该行调整2025至2027年财务预测，对于利润率有更乐观的 预测，考虑到好于该行预期的费用管控及管线出海后海外研发转移至合作伙伴，将DCF模型预测起始年 份滚动至2026年，上调目标价至78港元，维持"买入"评级。 交银国际发表研究报告指，康诺亚上半年核心品种市场渗透加速，差异化布局。其司普奇拜单抗首个完 整半年商业化成绩优异，TSLP/IL-13双抗有望成为自免领域下一代重磅单品，重点布局鼻科适应症。该 行又指，康诺亚借助强大的临床开发执行力及差异化显著的多种技术平台，公司跨技术路径、跨疾病领 域的多元产品矩阵逐步成型，并从自免和肿瘤进一步延展至更多大潜力治疗领域。 ...

Investment Rating - The report assigns a "Buy-A" investment rating to the company, with a 6-month target price of 78.83 HKD [5][3]. Core Insights - The company reported a revenue of 499 million CNY and a net profit of -79 million CNY for the first half of 2025. The core product, IL-4R monoclonal antibody Siponimod, is progressing well in commercialization, achieving sales of 170 million CNY in the first half of 2025. The product has been approved for three indications and is expected to enter negotiations for inclusion in the medical insurance directory, which could accelerate sales growth in the domestic market [1][3]. - The company has a diverse early-stage pipeline, with several products in various stages of clinical trials, including CM512 for moderate to severe atopic dermatitis and chronic rhinosinusitis with nasal polyps, and CM336 for relapsed or refractory multiple myeloma [2][3]. Financial Projections - Revenue projections for the company are estimated at 750 million CNY in 2025, 1.11 billion CNY in 2026, and 2.08 billion CNY in 2027. Net profits are expected to be -440 million CNY in 2025, -410 million CNY in 2026, and a positive 80 million CNY in 2027 [3][9]. - The company is expected to achieve a gross margin of 92% and a net margin of 3.6% by 2027, indicating a significant improvement in profitability as revenues grow [11][15]. Market Performance - The company's stock price was 66.50 HKD as of August 28, 2025, with a 12-month price range of 27.85 to 74.75 HKD. The stock has shown a relative return of 49.1% over the past three months and 68.5% over the past year [5][6]. Clinical Pipeline - The company has multiple products in its early pipeline, including CM512, CM518D1, CM336, and CM383, which are in various phases of clinical trials targeting conditions such as asthma, chronic obstructive pulmonary disease, and Alzheimer's disease [2][3].

Group 1: Nvidia - Blackwell Ultra deployment is progressing smoothly, but uncertainties remain regarding exports to China. FY2Q26 revenue reached $46.7 billion with a Non-GAAP gross margin of 72.7%, exceeding previous guidance [1] - Management has guided a median revenue of $54 billion for FY3Q26, with a median gross margin of 73.5%. If export conditions allow, an additional $2-5 billion in revenue could be generated [1] - The launch of Spectrum XGS and the progress of the Rubin series are in line with expectations, although the performance improvement of Rubin over Blackwell remains unclear [2] Group 2: Ctrip Group - Ctrip's Q2 performance exceeded expectations, with hotel business growth surpassing forecasts and market share continuing to rise. The company is well-positioned in the current competitive environment [3] - The target price has been adjusted to HKD 653 based on a 20x 2026 P/E ratio, maintaining a buy rating [3] Group 3: Meituan - Meituan's Q2 revenue grew by 12% year-on-year, but adjusted net profit fell by 89% due to irrational competition in the industry [6] - The company expects intensified competition in the third quarter, leading to a projected loss exceeding 15 billion yuan [6][7] Group 4: China National Heavy Duty Truck Group - The company reported a 4.2% year-on-year increase in revenue for the first half of 2025, with net profit rising by 4.0%, aligning with market expectations [8] - The target price is set at HKD 26.45, reflecting a 9.9x P/E ratio for 2025, with a focus on structural recovery in heavy truck sales [8] Group 5: China Innovationpay - The company experienced a 31.7% year-on-year revenue increase in the first half of 2025, with a significant 109.7% growth in energy storage battery revenue [9] - The target price is maintained at HKD 24.77, anticipating a concentrated release of delivery capacity in 2026 [10] Group 6: Innovent Biologics - The company reported a 37% year-on-year increase in product revenue for the first half of 2025, with net profit reaching 830 million yuan [11] - The target price has been raised to HKD 105, reflecting a positive outlook on the company's pipeline and commercialization efforts [12] Group 7: China Life Insurance - The company saw a 6.9% year-on-year increase in net profit for the first half of 2025, although growth has slowed compared to Q1 [18] - The target price has been adjusted to HKD 30, based on a 1.4x P/B ratio for 2025 [19] Group 8: China Pacific Insurance - The company achieved a 32.3% year-on-year increase in net profit for the first half of 2025, with strong performance in both underwriting and investment [20] - The target price has been raised to HKD 24, reflecting improved profitability and competitive advantages [21] Group 9: Yasheng Group - The company reported an 8.3% year-on-year decline in total revenue for the first half of 2025, primarily due to proactive business scale adjustments [22] - The target price is maintained at HKD 3.20, with expectations for recovery as margins stabilize [23] Group 10: XinAo Energy - The company experienced a slight 1% year-on-year decline in core profit for the first half of 2025, meeting market expectations [24] - The target price has been adjusted to HKD 73.66, reflecting a cautious outlook on retail gas demand [24]

交银国际研究 财务模型更新 | 医药 | 收盘价 | | 目标价 | | 潜在涨幅 | 2025 年 8 月 28 日 | | --- | --- | --- | --- | --- | --- | --- | | 港元 | | 66.50 | 港元 | 78.00↑ | +17.3% | | | 康诺亚 (2162 HK) | | | | | | | 1H25 核心品种市场渗透加速，差异化布局，上调目标价 司普奇拜单抗首个完整半年商业化成绩优异，TSLP/IL-13 双抗有望成为自免领 域下一代重磅单品，重点布局鼻科适应症。借助强大的临床开发执行力及差 异化显著的多种技术平台，公司跨技术路径、跨疾病领域的多元产品矩阵逐 步成型，并从自免和肿瘤进一步延展至更多大潜力治疗领域。上调目标价。 个股评级 买入 1 年股价表现 资料来源 : FactSet 8/24 12/24 4/25 8/25 -20% 0% 20% 40% 60% 80% 100% 120% 140% 2162 HK 恒生指数 股份资料 | 52周高位 (港元) | 74.75 | | --- | --- | | 52周低位 (港元) | 27 ...

Investment Rating - The report maintains a "Buy" rating for the company [8] Core Insights - The company reported a revenue of 499 million RMB for 1H25, representing an 812% year-over-year increase, driven by strong sales of Supacizumab in the AD field and unique indications in the nasal area [1][2] - The company plans to participate in the 2025 medical insurance negotiations, which is expected to enhance drug accessibility [1] - The early pipeline shows significant global potential, with CMG901 expected to report results in 2026 and CM512 anticipated to release AD clinical data in 2H25 [1][4] Summary by Sections Sales Performance - Supacizumab sales reached approximately 169 million RMB in 1H25, with expectations for continued growth due to its efficacy advantages over competitors and the upcoming allergy season [2] - The company is preparing to launch an injection pen formulation, which is expected to enhance convenience for patients [2] Early Pipeline Development - CM512 is positioned as a potential treatment for multiple indications, including AD and asthma, with ongoing clinical trials showing promise [3] - The company has clear upcoming milestones for CMG901, with a global Phase III trial for gastric cancer expected to report results in 2026 [4] Financial Health - The company reported a net loss of 78.8 million RMB in 1H25, a 77% reduction in losses year-over-year, with cash reserves of approximately 2.796 billion RMB [5] - The company plans to invest around 300 million RMB in capital expenditures for capacity expansion [5] Profitability Forecast - The revenue forecast for 2025 is adjusted to 727 million RMB, with net profit estimates for 2025 and 2026 at -742 million RMB and -604 million RMB, respectively [6][12] - The target price based on DCF valuation is set at 90.89 HKD, reflecting an increase from the previous estimate of 56.05 HKD [6][12]

里昂发布研报称，康诺亚-B(02162)上半年业绩超出市场预期，Stapokibart销售额达1.69亿元人民币，高 于先前指引的1.5亿元人民币。虽然CM512潜在的二次对外授权机会推动近期股价上升，但公司优先聚 焦国内市场的产品开发策略令市场稍为失望。考虑到CM512展现的积极临床进展及成为同类最佳药物 的潜力，该行将康诺亚的目标价由65港元上调至78港元，评级由高度确信跑赢大市调整至跑赢大市。 ...

Core Viewpoint - 康诺亚-B (02162) reported better-than-expected performance for the first half of the year, with Stapokibart sales reaching 169 million RMB, exceeding the previous guidance of 150 million RMB [1] Group 1: Financial Performance - Stapokibart sales amounted to 169 million RMB, surpassing the earlier forecast of 150 million RMB [1] - The company's focus on domestic product development strategies has led to some market disappointment despite the positive sales figures [1] Group 2: Market Outlook - The potential for CM512's secondary licensing opportunities has contributed to a recent increase in stock price [1] - Given the promising clinical progress of CM512 and its potential to become a best-in-class drug, the target price for 康诺亚 has been raised from 65 HKD to 78 HKD [1] - The rating for 康诺亚 has been adjusted from "highly confident to outperform the market" to "outperform the market" [1]

Core Viewpoint - The company reported strong revenue growth in 1H25, driven by licensing agreements and product sales, with a significant increase in income from its core product CM310 [1][2] Group 1: Financial Performance - The company achieved a revenue of 499 million yuan in 1H25, representing a year-on-year increase of 812% [1] - Product sales revenue reached 169 million yuan, while the net loss attributable to shareholders was 79 million yuan [1] - The revenue exceeded expectations primarily due to upfront payments and recent confirmations from licensing agreements for CM313 and CM355, contributing a total of 318 million yuan to the income [2] Group 2: Product Development and Market Position - CM310 has received approval for three indications: moderate to severe atopic dermatitis (AD), seasonal allergic rhinitis (SAR), and chronic rhinosinusitis with nasal polyps (CRSwNP) [1] - The sales contribution from CM310 in 1H25 was 169 million yuan, aligning with expectations [1] - The company has expanded its commercialization team to 370 members and plans to continue hiring [1] - CM310 is priced at 1,812 yuan per unit, with a promotional offer of buy two, get one free, and the company is advised to monitor the upcoming medical insurance negotiations [1] Group 3: Strategic Collaborations - The company has established a global exclusive licensing agreement with AstraZeneca for CLDN 18.2 ADC (CMG901), which is currently in a Phase III MRCT study for advanced gastric and gastroesophageal junction adenocarcinoma [2] - CM313 and CM355 have been licensed to Timberlyne and Prolium, respectively, enhancing the company's revenue through upfront and recent payments [2] - Ongoing clinical trials for CM512, CM536, and CM336 are progressing, with CM336 receiving its first overseas IND approval [2] Group 4: Profit Forecast and Valuation - The company's loss forecast for 2025 has been adjusted from 837 million yuan to 524 million yuan due to the positive impact of licensing agreements [2] - The profit forecast for 2026 remains largely unchanged [2] - The target price has been raised by 54.5% to 85.00 HKD, indicating a potential upside of 16.8% from the current stock price [2]

Market Performance - The Hang Seng Healthcare Index (HSHCI) decreased by 1.23% as of August 28, 2025, with mixed performance among constituent stocks [3] - The Hang Seng Medical ETF (513060) fell by 1.15%, with a latest price of 0.69 yuan, but showed a 6.26% increase over the past month, ranking in the top third among comparable funds [3] - The Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index (HSSCPB) dropped by 1.02%, with the Hong Kong Innovative Drug Selection ETF (520690) down by 0.81% to 0.98 yuan [4] Company Highlights - Innovent Biologics reported a 50.6% year-on-year revenue increase to 5.95 billion yuan for the first half of 2025, achieving a gross margin of 86% and a net profit of 830 million yuan, driven by pipeline expansion in oncology and new product launches [4] - The company has over 2 billion USD in cash reserves to support future innovation pipeline advancements [4] Policy and Industry Developments - The Ministry of Commerce and Jiangsu Provincial Government issued a plan to enhance the biopharmaceutical industry in Jiangsu Free Trade Zone by 2030, focusing on large molecule biologics, cell and gene therapy, and innovative medical devices [5] - Recent market pressure on the pharmaceutical sector was noted, with the Hang Seng Healthcare Index dropping over 2.1%, influenced by U.S. tariff proposals on imported drugs that could disrupt the global pharmaceutical industry [5] Analyst Insights - Analysts suggest that the recent decline in the Hong Kong pharmaceutical sector is a short-term fluctuation and does not alter the long-term industry outlook, with ongoing favorable policies expected to drive more cross-border business development transactions [6] - The Chinese innovative drug assets are gaining international recognition, presenting structural opportunities in the medium to long term [6] ETF Performance and Metrics - The Hang Seng Medical ETF has seen a significant increase in scale by 46.87 million yuan this month, ranking in the top third among comparable funds [8] - The ETF's share count increased by 92.5 million shares over the past week, also ranking in the top third [9] - The ETF recorded a net inflow of 74.96 million yuan recently, with a total of 65.92 million yuan accumulated over the last five trading days [10] - The ETF's financing net purchase reached 2.5072 million yuan this month, with a financing balance of 268 million yuan [11] Risk and Return Metrics - The Hang Seng Medical ETF has achieved a 48.60% net value increase over the past two years, with a maximum monthly return of 28.34% since inception [11] - The ETF's Sharpe ratio for the past year is 2.41, indicating strong risk-adjusted returns [12] - The ETF has the lowest relative drawdown among comparable funds, with a drawdown of 0.63% year-to-date [13] Valuation Insights - The latest price-to-earnings ratio (PE-TTM) for the Hang Seng Medical ETF is 30.9, which is below the historical average, indicating a potentially undervalued position [15]